CARISEL: Clinical Outcomes by Implementation Strategy of Patients Receiving LA CAB + RPV in European Healthcare Settings

Source: CCO Independent Conference Coverage: Clinical Impact of New HIV Data From Fall 2022 Conferences*
Download Slideset
Washington, DC - October 19-23, 2022; Glasgow, Scotland and virtual - October 23-26, 2022
Long-acting cabotegravir plus rilpivirine was effective and well tolerated at 12 months regardless of implementation support in this phase IIIb study.
Format: Microsoft PowerPoint (.ppt)
File Size: 152 KB
Released: October 26, 2022

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings